A teaser image displaying the first page of PhRMA's report, displaying the title text: The Biopharmaceutical Industry's Sustained Commitment to Inspiring and Advancing Tomorrow's STEM Workforce

Research finds strong linkages between STEM-intensive industries and desirable innovation and economic outcomes, including the creation of high-growth, high-quality jobs with bright career prospects; new inventions as reflected in patent filings; the development of vibrant technology-driven startups; and ultimately, sustained economic growth and global competitiveness. The innovative biopharmaceutical industry demonstrates these characteristics by leveraging STEM talent throughout every aspect of a medicine’s life cycle, and with a STEM workforce concentration more than five times that of other industries. Yet despite the recognition of the critical role of the STEM workforce to the nation’s innovation economy and growth and amid calls to bolster the country’s manufacturing capacity, the U.S. continues to lag behind other countries in terms of STEM literacy and expertise. Recognizing these challenges, the biopharmaceutical industry has made a significant, sustained commitment to enhancing the nation’s STEM education and talent pipeline by inspiring and developing the next generation of scientists, engineers, and technology professionals. PhRMA member companies have dedicated significant resources to these pursuits and are reaching an impressive, nationwide scale.

A teaser image displaying the first page of PhRMA's report, displaying the title text: The Biopharmaceutical Industry's Sustained Commitment to Inspiring and Advancing Tomorrow's STEM Workforce

This website uses cookies and other tracking technologies to optimize performance, preferences, usage, and statistics. By clicking “Accept All”, you consent to store on your device the cookies and other tracking technologies that require consent. You can tailor or change your preferences by clicking “Manage My Cookies”. You can check our privacy policy for more information.